A235980 Stock Overview
MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MedPacto, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩9,790.00 |
| 52 Week High | ₩23,900.00 |
| 52 Week Low | ₩6,110.00 |
| Beta | 0.86 |
| 1 Month Change | -39.12% |
| 3 Month Change | 18.38% |
| 1 Year Change | -55.60% |
| 3 Year Change | -87.50% |
| 5 Year Change | n/a |
| Change since IPO | -45.46% |
Recent News & Updates
Shareholder Returns
| A235980 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 1.5% | 5.4% | 3.4% |
| 1Y | -55.6% | 6.7% | 7.1% |
Price Volatility
| A235980 volatility | |
|---|---|
| A235980 Average Weekly Movement | 14.2% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Volatility Over Time: A235980's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 62 | Seong-Jin Kim | www.medpacto.com |
MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea.
MedPacto, Inc. Fundamentals Summary
| A235980 fundamental statistics | |
|---|---|
| Market cap | ₩328.76b |
| Earnings (TTM) | -₩35.32b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.3x
P/E RatioIs A235980 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A235980 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩35.32b |
| Earnings | -₩35.32b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.05k |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did A235980 perform over the long term?
See historical performance and comparison